EUCTR2008-007797-37-HU进行中（未招募）不适用
A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three different oral doses of AZD1386 and Placebo in patients with Osteoarthritis of the knee
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures.
- •2. Patients with OA of the knee that have unsatisfactory pain relief from past or on going nsNSAIDs/COX-2s and paracetamol/acetaminophen treatment either consecutively or simultaneously at recommended doses for at least 2 weeks, or with intolerability to past or on-going nsNSAIDs/COX-2s irrespective of doses, or dosing period, as judged by the investigator. Patients that have intolerability to NSAIDs/Cox-2s must have tried acetaminophen/paracetamol for at least 2 weeks at any time with unsatisfactory pain relief.
- •3. WOMAC pain on walking must be =40 mm and =90 mm VAS on both enrolment V1 and randomisation V2.
- •4. Male, or non-pregnant females, =40 and <80 years of age.
- •5.Symptomatic primary OA of the knee for at least 3 months prior to V1 according to the American College of Rheumatology (ACR).
- •6. Patients should belong to ACR global functional status class I, II or III (and should not be limited in their ability to perform usual self care i.e. not belong to class IV).
- •7. One knee should be designated as the target joint. The pain in the target joint must exceed pain experienced in other joints, and/or must exceed pain experienced from any concomitant medical condition.
- •8. OA in the target knee should be confirmed by X-ray at any time prior to randomisation, classified at least grade 2 according to Kellgren.
- •9. Women of child bearing potential are eligible for participation in the study if they have a negative pregnancy test at enrolment (V1) and at randomisation (V2), see Appendix D for further guidance.
- •10. Patients must be both willing and able to comply with and understand the study requirements
- •In addition, following criterion must be fulfilled for inclusion into the optional genetic research:
- •11. Provision of signed, written and dated informed consent for genetic research
- •If a patient declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this clinical study protocol, so long as they consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A current diagnosis of another form of arthritis, in addition to OA (e.g. rheumatoid arthritis, gout, septic arthritis, juvenile arthritis and lupus erythematosus) or wide spread chronic pain or fibromyalgia.
- •2. Patients with intra-articular or intramuscular corticosteroids or intra-articular hyaluronic acid injections within 3 months prior to randomisation.
- •3. Oral use of corticosteroids, barbiturates, rifampicin or phenytoin within 6 weeks prior to the randomisation visit.
- •4. Analgesic treatment, except low dose aspirin up to 325 mg/day for cerebrovascular and cardiovascular profylaxis.
- •5. Concomitant use of strong and moderate CYP3A4 enzyme inhibitors, such as ketoconazole, itraconazole, clarithromycin, nefazodone, erythromycin, fluconazole, aprepitant, diltiazem, verapamil, grapefruit juice, HIV protease inhibitors.
- •6. Within the last month prior the enrolment visit using >4 gram/ day (Japan: >1.5 gram/ day) of paracetamol/acetaminophen.
- •7. Within the last month prior the enrolment visit using more than the highest recommended dose of any NSAIDs or COX-2 inhibitors.
- •8. History, and/or presence, of somatic disease/condition, which may interfere with the objectives of the study as judged by the investigator.
- •9. Malabsorption, gastrointestinal disorder or surgery leading to impaired drug absorption.
- •10. History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.
- •11. Risk factors for ventricular fibrillation e.g. family history of Short QT syndrome (SQTS) or sudden cardiac death (SCD) amongst first-degree relatives.
- •12. QTcF interval < 350 msec or > 450 msec at enrolment.
- •13. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain.
- •14. Enrolment laboratory value for ALT, AST >2 times the upper limit of normal range.
- •15. Known positive test result for human immunodeficiency virus (HIV) antibody, hepatitis B surfactant antigen (HbsAg) or hepatitis C antibody.
- •16. Clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator.
- •17. Breast-feeding women.
- •18. Positive pregnancy test.
- •19. Donation of plasma within the two weeks prior to the enrolment visit and/or donation of blood within the three months prior to the enrolment visit and during the study.
- •20. History of allergic reaction to paracetamol/acetaminophen.
- •21. Involvement in the planning and conduct of the study (applies to both AZ staff and the staff at the study site).
- •22. Participation in another clinical trial, use of any investigational drugs or procedures or use of experimental medications within 30 days prior to the enrolment visit.
- •23. According to the investigator the patient should not participate in the study.
- •In addition, the following criteria are regarded as criteria for exclusion from the genetic research:
- •24. Previous bone marrow or stem cell transplant.
- •25. Whole blood transfusion within 120 days of the date of genetic sample collection.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three different oral doses of AZD1386 and Placebo in patients with Osteoarthritis of the kneeOsteoarthritis of the kneeMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisMedDRA version: 9.1Level: LLTClassification code 10031165Term: Osteoarthritis kneeEUCTR2008-007797-37-BGAstraZeneca AB520
进行中（未招募）
不适用
A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three different oral doses of AZD1386 and Placebo in patients with Osteoarthritis of the kneeOsteoarthritis of the kneeMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisMedDRA version: 9.1Level: LLTClassification code 10031165Term: Osteoarthritis kneeEUCTR2008-007797-37-FIAstraZeneca AB520
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmPrevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.MedDRA version: 20.0 Level: LLT Classification code 10028154 Term: Multi-organ failure System Organ Class: 100000004867EUCTR2014-000899-25-GBFaron Pharmaceuticals Ltd152
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmPrevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.MedDRA version: 20.0 Level: LLT Classification code 10036654 Term: Prevention System Organ Class: 100000022817MedDRA version: 20.0 Level: PT Classification code 10002885 Term: Aortic aneurysm repair System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0 Level: PT Classification code 10002886 Term: Aortic aneurysm rupture System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: LLT Classification code 10028154 Term: Multi-organ failure System Organ Class: 100000167648EUCTR2014-000899-25-EEFaron Pharmaceuticals Ltd152
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmEUCTR2014-000899-25-FIFaron Pharmaceuticals Ltd152